文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗白血病

自体造血干细胞移植后治疗相关髓系肿瘤前白血病克隆的早期检测与演变

Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT.
PubMed 文献 · Blood · 2018-01-08

本研究对自体造血干细胞移植(ASCT)后发生的治疗相关髓系肿瘤(tMN)进行全外显子测序和靶向深度测序,发现tMN突变数显著高于原发骨髓增生异常综合征(中位27 vs 12个突变,P=0.001),且70%的tMN患者移植材料中可检出低变异等位基因频率的tMN突变,克隆模式重建显示前恶性克隆可在tMN诊断前7年以上存在。

要点

  • tMN突变数显著高于原发MDS(中位27 vs 12个突变,P=0.001),且缺乏明确衰老特征。
  • 70%的tMN患者移植材料中可检出低VAF的tMN突变,提示前恶性克隆在移植时已存在。
  • 前恶性克隆可在tMN诊断前7年以上检出,ASCT后治疗可能影响克隆选择。

核心结论

  • ASCT后tMN起源于携带(前)tMN突变的造血干细胞,这些突变在疾病发病前数年即已存在,且ASCT后治疗可影响这些克隆的选择。
  • 早期检测前恶性克隆并监测其演变轨迹可能有助于预测tMN发生并在未来指导早期干预。

研究设计与样本

  • 研究采用全外显子测序(WES)和靶向深度测序(TDS)对系列(前)tMN样本进行分析。
  • 研究对象为ASCT后发生tMN的患者,比较tMN与原发骨髓增生异常综合征(MDS)的突变特征。

主要发现

  • WES显示tMN突变数显著高于原发MDS(中位27 vs 12个突变;P=0.001)。
  • tMN突变缺乏明确衰老特征,与原发MDS不同,提示不同突变机制。
  • 部分患者tMN突变同时存在于髓系和T细胞中,提示tMN可能起源于早期造血干细胞。
  • tMN与先前恶性肿瘤的突变谱不重叠,排除共同起源。
  • TDS在70%的tMN患者移植材料中检出低变异等位基因频率(VAF)的tMN突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy-related myeloid neoplasms (tMNs) are severe adverse events that can occur after treatment with autologous hematopoietic stem cell transplantation (ASCT). This study aimed to investigate the development of tMNs following ASCT at the molecular level by whole-exome sequencing (WES) and targeted deep sequencing (TDS) in sequential (pre-) tMN samples. WES identified a significantly higher number of mutations in tMNs as compared with de novo myelodysplastic syndrome (MDS) (median 27 vs 12 mutations; P = .001). The mutations found in tMNs did not carry a clear aging-signature, unlike the mutations found in de novo MDS, indicating a different mutational mechanism. In some patients, tMN mutations were identified in both myeloid and T cells, suggesting that tMNs may originate from early hematopoietic stem cells (HSCs). However, the mutational spectra of tMNs and the preceding malignancies did not overlap, excluding common ancestry for these malignancies. By use of TDS, tMN mutations were identified at low variant allele frequencies (VAFs) in transplant material in 70% of the patients with tMNs. Reconstruction of clonal patterns based on VAFs revealed that premalignant clones can be present more than 7 years preceding a tMN diagnosis, a finding that was confirmed by immunohistochemistry on bone marrow biopsies. Our results indicate that tMN development after ASCT originates in HSCs bearing (pre-)tMN mutations that are present years before disease onset and that post-ASCT treatment can influence the selection of these clones. Early detection of premalignant clones and monitoring of their evolutionary trajectory may help to predict the development of tMNs and guide early intervention in the future.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Berger G, Kroeze LI, Koorenhof-Scheele TN, et al. Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. Blood. 2018. PMID: 29311096. doi:10.1182/blood-2017-09-805879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。